focalinterest.net

AI Summary of Scholarly Research

This page presents an AI-generated summary of a published research paper. The original authors did not write or review this article. [See full disclosure ↓]

Microneedle biosensor tracked drug clearance and organ dysfunction in vivo

Written by

editor@focalinterest.com

in

Research area:medicine-clinical

What the study found

The study found that a resilient nanostructured bioelectrode in a microneedle format could support longitudinal in vivo monitoring of low-concentration analytes and organ function. It was used to track pharmacokinetics, meaning how a drug moves through the body over time, and to assess hepatic and renal clearance.

Why the authors say this matters

The authors conclude that this platform enables minimally invasive, longitudinal monitoring and real-time assessment of organ function. They also say it may support precision dosing of narrow therapeutic index drugs, meaning medicines that require very careful dose control.

What the researchers tested

The researchers developed a microneedle-based resilient nanostructured bioelectrode using a bilayer process with a micrometer-thick gold adhesion layer and controlled dealloying. They tested its electrochemical performance, durability, and ability to integrate receptor-based biosensors, and then used it in freely moving rats and in a blood-interstitial fluid equilibrium-based bioanalytical framework.

What worked and what didn't

The resulting microneedles were described as corrosion resistant, stable over a wide potential window, and resistant to abrasion in stiff tissues. The platform extended in vivo biosensor lifetime to 6 days and allowed blood-equivalent pharmacokinetic parameters to be derived accurately; in liver-damaged models it showed delayed irinotecan clearance, and in kidney disease models it tracked antibiotic pharmacokinetics, detected renal impairment earlier than conventional biomarker thresholds, and captured recovery under treatment.

What to keep in mind

The available summary does not describe detailed study limitations. The findings are reported for preclinical models in rats and disease models, so the abstract does not state whether the results directly extend to human use.

Key points

  • A resilient microneedle bioelectrode was developed for in vivo electrochemical sensing.
  • The platform was reported to be corrosion resistant, abrasion immune, and stable across a wide potential window.
  • Biosensor lifetime for pharmacokinetics monitoring was extended to 6 days in a freely moving rat.
  • The system derived blood-equivalent pharmacokinetic parameters and was used to assess hepatic and renal clearance.
  • It detected delayed irinotecan clearance in liver-damaged models and earlier renal impairment than conventional biomarker thresholds.
  • The abstract reports tracking of recovery during therapeutic intervention in kidney disease models.

Disclosure

Research title:
Microneedle biosensor tracked drug clearance and organ dysfunction in vivo
Authors:
Jialun Zhu, Xuanbing Cheng, M. Bahman Bahramian, Kuanming Yao, Zongqi Li, Boyu Hu, Tsung‐Yu Wu, Kiarash A. Sabet, Jiarui Cui, Jiawei Tan, Junjie Fang, Yifu Li, Connie Ho, Joshua Ng, Anthony Sung, Isabel Romero, Shuyu Lin, Y Zhao, Kaiji Zhang, Ryan Chaiyakul, Hanie Yousefi, Connor D. Flynn, Jagotamoy Das, David Jelínek, Laurent Voisin, Aaron Ambrus, Ao Zhang, Yitian Chi, Yu Chen, Chong Liu, Hilary A. Coller, Benjamin M. Wu, Nanthia Suthana, Shana O. Kelley, Carlos Milla, Ira Kurtz, Sam Emaminejad
Institutions:
BioElectronics (United States), BioElectronics (United States), BioElectronics (United States), BioElectronics (United States), BioElectronics (United States), BioElectronics (United States), BioElectronics (United States), BioElectronics (United States), BioElectronics (United States), BioElectronics (United States), BioElectronics (United States), BioElectronics (United States), BioElectronics (United States), BioElectronics (United States), BioElectronics (United States), BioElectronics (United States), BioElectronics (United States), BioElectronics (United States), BioElectronics (United States), Boston Children's Hospital, California NanoSystems Institute, California NanoSystems Institute, Center for Pain and the Brain, Chan Zuckerberg Biohub Chicago, Chan Zuckerberg Biohub Chicago, Chan Zuckerberg Biohub Chicago, Chan Zuckerberg Initiative (United States), Chan Zuckerberg Initiative (United States), Chan Zuckerberg Initiative (United States), Duke University, Florida State University, Florida State University, Florida State University, Massachusetts Institute of Technology, Northwestern University, Northwestern University, Samueli Institute, Samueli Institute, Samueli Institute, Samueli Institute, Samueli Institute, Samueli Institute, Samueli Institute, Somerville Hospital, Stanford Medicine, University of California, Los Angeles, University of California, Los Angeles, University of California, Los Angeles, University of California, Los Angeles, University of California, Los Angeles, University of California, Los Angeles, University of California, Los Angeles, University of California, Los Angeles, University of California, Los Angeles, University of California, Los Angeles, University of California, Los Angeles, University of California, Los Angeles, University of California, Los Angeles, University of California, Los Angeles, University of California, Los Angeles, University of California, Los Angeles, University of California, Los Angeles, University of California, Los Angeles, University of California, Los Angeles, University of California, Los Angeles
Publication date:
2026-04-01
DOI:
10.1126/scitranslmed.adr5493
OpenAlex record:
View
AI provenance: This post was generated by gpt-5.4-mini (OpenAI). The original authors did not write or review this post.

More posts